Background-Patients with congestive heart failure (CHF) often have low serum triiodothyronine (T 3 ) concentrations. In a rodent model of myocardial infarction-induced CHF and low serum T 3 , we hypothesized that replacing T 3 to euthyroid levels would improve left ventricular function without producing untoward signs of thyrotoxicosis. Methods and Results-Adult male Sprague-Dawley rats were subjected to left anterior descending coronary artery ligation (myocardial infarction). One week post-myocardial infarction, left ventricular fractional shortening was significantly reduced to 22Ϯ1% in CHF animals versus 38Ϯ1% for sham-operated controls (PϽ0.001). Serum T 3 concentration was also significantly reduced (80Ϯ3 versus 103Ϯ6 ng/dL; PϽ0.001), in CHF animals versus Shams. At 9 weeks post-myocardial infarction, systolic function (ϩdP/dt max) was significantly attenuated in CHF animals (4773Ϯ259 versus 6310Ϯ267 mm Hg/s; PϽ0.001) as well as diastolic function measured by half time to relaxation (15.9Ϯ1.2 versus 11.1Ϯ0.3 ms; PϽ0.001). ␣-myosin heavy chain expression was also significantly reduced by 77% (PϽ0.001), and ␤-myosin heavy chain expression was increased by 21%. Continuous T 3 replacement was initiated 1 week post-myocardial infarction with osmotic mini-pumps (6 g/kg/d), which returned serum T 3 concentrations to levels similar to Sham controls while resting conscious heart rate, arterial blood pressure and the incidence of arrhythmias were not different. At 9 weeks, systolic function was significantly improved by T 3 replacement (6279Ϯ347 mm Hg/s; PϽ0.05) and a trend toward improved diastolic function (12.3Ϯ0.6 ms) was noted. T 3 replacement in CHF animals also significantly increased ␣and reduced ␤-MHC expression, (PϽ0.05). Conclusions-These data indicate that T 3 replacement to euthyroid levels improves systolic function and tends to improve diastolic function, potentially through changes in myocardial gene expression. (Circ Heart Fail. 2009;2:243-252.) 
Clinical Perspective on p 252
Thyroid hormone metabolism is altered in patients with congestive heart failure (CHF) and frequently leads to low serum T 3 concentrations. The reduction in serum T 3 has been correlated with poor left ventricular (LV) function in a rodent model 14 and serves as a strong predictor of short-term outcome in CHF patients. 15 It follows that T 3 replacement could reverse these outcomes as recent reports have demonstrated a hemodynamic benefit for such therapy. 16 -18 However, T 3 supplementation has the potential to cause adverse side effects, such as an increase in metabolic rate, systemic oxygen demand, heart rate, and arrhythmias. 2 There are several studies on the effects of thyroid hormone supplementation in animal models of CHF. 11, 19, 20 These prior reports have studied both thyroxine (T 4 ) and T 3 administration; however recent investigations have demonstrated that in the setting of CHF, T 4 would not be expected to be optimally effective due to reduced peripheral conversion of the prohormone T 4 to the active hormone T 3 . 19 -21 Only 1 prior report has given replacement doses of T 3 in a physiological replacement protocol to avoid the potential adverse effects of excess T 3 treatment. 20 The specific objectives of the present study were to (1) continuously administer a replacement dose of T 3 over an 8 weeks time period to animals with LV dysfunction and low T 3 syndrome, (2) analyze the effects of T 3 replacement on serum T 3 and T 4 concentrations, as well as serial measurements of LV structure and function by echocardiography, (3) identify, in real-time, changes in heart rate, blood pressure, ECG, and temperature indicative of thyrotoxicosis in conscious animals, using implanted radiotelemetry transmitters, (4) directly assess LV function by cardiac catheterization, and (5) measure changes in myocardial ␣and ␤-MHC mRNA levels to correlate changes in gene expression with physiological outcomes. Data are presented to indicate that T 3 replacement to euthyroid levels improves systolic function and tends to improve diastolic function, potentially through changes in myocardial gene expression.
Methods
All animal protocols were approved by the Loyola University Chicago Institutional Animal Care and Use Committee. LV structure and function were assessed by transthoracic M-mode and 2D echocardiography (Acuson Sequoia C256, 15L8 transducer (15 MHz) , Siemens Medical Solutions, Pa) in 55 adult male Sprague-Dawley rats (294Ϯ2.3 g) under isoflurane anesthesia (4%). Echocardiography and their corresponding hemodynamic measurements were made by a single, "blinded" echocardiographer. Myocardial infarction (MI) surgery: 44 animals underwent coronary artery ligation. 22, 23 Because of the severity of the infarct, 9 animals did not recover. Detailed methods are presented in the online supplement. Sham operations on 11 animals were identical, except the suture around the coronary artery was not ligated. LV structure and function were assessed with echocardiography 1 week post-MI-surgery, and the degree of LV dysfunction independently graded on a scale of 1 to 5 by 2 of the investigators (A.M.S., K.K.H.). Animals were divided into groups with equal levels of LV dysfunction. In our hands, this MI procedure produces a large anterior wall MI and segmental LV dysfunction, leading to pressure and volume overload and subsequent LV remodeling of the noninfarcted myocardium. 24, 25 
T 3 Delivery
One week post-MI, osmotic mini-pumps (Model No. 2004, Alzet, Calif) were implanted subcutaneously at the nape of the neck to continuously deliver saline diluent in Sham animals (Nϭ11) or Figure 1. Experimental timeline and 1 week postsurgery echocardiography: Serum T 3 and T 4 , and LV structure and function were assessed at 0, 1, 3, 5, 7, and 9 weeks. MI or Sham surgeries were performed at 0 weeks. Animals were then divided into groups with equal levels of LV dysfunction, and osmotic pumps with saline or T 3 were implanted at 1 week. Osmotic pumps were replaced at 5 weeks. At 9 weeks the LV was catheterized to assess LV function, animals were then euthanized, and tissue collected for analysis. Long axis and M-Mode echocardiograms for a Sham and MI animal, 1 week postsurgery, are shown below.
MI-saline control animals (Nϭ15); and T 3 at 3 g/kg/d (Nϭ6), 6 g/kg/d (Nϭ10), or 60 g/kg/d (Nϭ4). Osmotic pumps were replaced at the 4th week following echocardiography procedures.
Radiotelemetry
In a subset of animals (Nϭ9), radiotelemeters (Model C50-PXT, Data Sciences International, St. Paul, Minn) were used to monitor blood pressure, ECG, body temperature, and physical activity. For these studies, there were 3 groups of MI animals (3 animals/group) receiving saline, 6 gT 3 /kg/d or 60 gT 3 /kg/d. Importantly, the level of LV dysfunction was identical in each group. Telemetry data were collected once a week for 3 hours, during the light (resting/sleeping) cycle of the day.
Serum T 3 and T 4 Concentrations and LV Structure and Function
At 1, 3, 5, 7, and 9 weeks post-MI surgery, rats were anesthetized with isoflurane (3% to 5%) and blood samples (1 mL) were obtained from the tail vein or the retro-orbital venous plexus. Blood was kept on ice until centrifuged at 16 000g for 15 minutes at 4°C. Serum samples were collected to measure T 3 and T 4 concentrations using a chemiluminescence assay (Roche Elecsys). After the blood draw, surface ECG leads were attached to monitor heart rate and arrhythmias, and M-mode and 2D echocardiographic images were obtained in the parasternal long and short axes. At the conclusion of the study (9 weeks), LV function was directly assessed in each animal. A 2-F Millar pressure-volume catheter (SPR-869, Houston, Tex) was advanced from the right carotid artery into the LV and baseline measurements of pressure were recorded. An abdominal incision was made to allow occlusion of the suprarenal vena cava to examine LV end systolic and diastolic pressure-volume relationships. The left jugular vein was then catheterized to administer a dobutamine bolus (20 g/kg) to examine changes in myocardial function after ␤ 1 -adrenergic stimulation.
Measurements of ␣ and ␤ MHC Gene Expression
Six age-and weight-matched animals were used as a control group for CHF animals receiving saline or T 3 at 6 or 60 g/kg/d. Total RNA was extracted from frozen LV samples using the guanidinium thiocyanate method, as previously described. 26 -28 Detailed methods are presented in the online supplement.
Statistical Analysis
Data are presented as meansϮSEM. Groups were compared using a t test, 1-way analysis of variance (ANOVA), or 2-way repeatedmeasures (RM) ANOVA (Holm-Sidak posthoc) as appropriate. Because serial blood samples were not always available for the same animal, serum T 3 and T 4 data were not analyzed with repeated measures. Instead, these data were analyzed at each time point. Some data were used for 2 comparisons. To account for the repeated analysis of these data sets, the significant value required for a t test was reduced to Pϭ0.025 and the significant value required for multiple comparisons following an ANOVA was reduced to PϽ0.01. Elsewhere, P values Յ0.05 were considered significant. Data were analyzed using Sigma Stat version 3.1 (Systat Software, Calif).
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Results

Coronary Artery Ligation Produces Significant LV Chamber Dilatation and LV Dysfunction
M-mode and 2D echocardiography were used to serially assess LV structure and function before and after sham surgery or coronary artery ligation. There were no significant differences in body weight, heart rate, or LV function in the animals before designating them for Sham or MI surgery (data not shown). The effect of surgery on coronary artery ligation on LV remodeling and function 1 week after surgery was examined by comparing presurgical baseline, 1 week Sham, and 1 week MI values. Infarct surgery caused significant LV remodeling and attenuated LV function within 1 week after surgery, as compared with sham-operated controls animals ( Figure 1 , Table) . LV anterior wall thickness was significantly reduced during systole and diastole. Additionally, LV volumes during systole and diastole were significantly increased, reflective of impaired contractile function and dilated cardiomyopathy. LV systolic function, as assessed by fractional shortening, and ejection fraction, was also significantly reduced in CHF animals. There were no significant effects of sham surgery on LV structure or function. The degree of LV dysfunction and remodeling were then ranked on a scale of 1 to 5, and animals were equally divided into different T 3 treatment groups based on their degree of LV dysfunction.
Administration of T 3 Reverses the low T 3 Syndrome in CHF Rats After Coronary Artery Ligation
To examine the effect of surgery or coronary artery ligation on serum T 4 and T 3 concentrations, presurgical baseline values were compared with 1 week Sham and 1 week MI animals. As seen in Figure 2A, 1 week after surgery, serum T 4 concentrations tended to be lower in Sham (Pϭ0.05) and MI animals (Pϭ0.05). As seen in Figure 2B , 1 week after surgery serum T 3 concentrations were significantly reduced by MI surgery versus baseline values (Pϭ0.012) and 1 week Sham controls (PϽ0.001). Sham surgery (Sham versus baseline), did not significantly change serum T 3 concentrations (Pϭ0.141). CHF animals were then assigned to receive saline, 3, 6, or 60 gT 3 /kg/d delivered by osmotic minipump, and serum T 4 and T 3 levels were serially measured every 2 weeks thereafter. CHF animals receiving saline had significantly lower T 3 concentrations than Sham-operated controls at 3 and 5 weeks postsurgery (Figure 2A and 2B). CHF rats receiving increasing concentrations of T 3 showed a significant dose-dependent decrease in serum T 4 concentration throughout the treatment period ( Figure 2A ). This confirmed the delivery of T 3 to the animals and reflects the negative pituitary feedback response to supplemental T 3 . 29 In contrast, the administration of T 3 dose dependently increased serum T 3 levels in CHF rats ( Figure 2B ). Importantly, a dose of 6 gT 3 /kg/d restored T 3 levels to those observed in Shamoperated controls ( Figure 2B ). Administration of 60 gT 3 / kg/d increased serum T 3 concentrations to levels significantly above those observed in either Sham-operated or salinetreated CHF rats.
Effects of T 3 Administration on Hemodynamic Variables in Conscious Animals
Radiotelemetry was used to assess the hemodynamic effects of T 3 administration on CHF rats to ascertain whether constant infusion of T 3 at 6, or 60 g/kg/d produced any evidence of cardiovascular side effects or thyrotoxicosis. As seen in Figure 3A , there was no significant effect of T 3 supplementation on resting/sleeping heart rate (Pϭ0.713) at any time point of the study. Resting ECGs were also recorded, and although occasional periods of 2°AV block were noted in all groups, there was no consistent increase in this arrhythmia with increasing doses of T 3 . T 3 supplementation tended to increase body temperature at each time point in the study ( Figure 3B ), but these values were not significantly different (Pϭ0.596). Systolic blood pressure was also not significantly altered by T 3 supplementation (Pϭ0.502; Figure 3C ). There was a trend for the highest concentration of T 3 (60 g/kg/d) to lower diastolic blood pressure ( Figure  3D ), in keeping with the known effect of T 3 to reduce systemic vascular resistance, but this was not significant (Pϭ0.135). There was no correlation between individual or group T 3 concentrations and heart rate, body temperature, mean arterial blood pressure, systolic, or diastolic blood pressure (Supplemental Figure I) . This is probably due to the relatively small changes in T 3 concentrations versus the thyrotoxic doses used in previous studies. Because of the small sample size in the telemetery data, a power analysis was used to calculate the number of animals required to demonstrate that the replacement dose of 6 gT 3 /kg/d increases resting heart rate in conscious animals. Using the average difference in heart rate and average standard deviation between the MIsaline and MI-6 g/kg/d animals over the 7 weeks of readings, the power analysis suggested that Ϸ50 animals/ group are needed to demonstrate a significant increase in heart rate of Ϸ10 bpm. This is somewhat expected as the experiments were designed to deliver a replacement dose of T 3 with minimal effects on heart rate, blood pressure, or body temperature. These data suggest that T 3 administration at 6 g/kg/d was sufficient to restore serum T 3 levels without producing overt signs of thyrotoxicosis. whether T 3 supplementation attenuated LV remodeling or improved LV function. Heart rate was measured in all animals under anesthesia during echocardiography ( Figure  4A ) and was similar to conscious heart rate data ( Figures 3A  and 4A ). Compared with MI-saline animals, heart rate measured under anesthesia was elevated in animals receiving 6 gT 3 /kg/d at the 9th week and in animals receiving 60 gT 3 /kg/d at the 3rd and 9th week. Single lead ECG recordings measured under isoflurane anesthesia indicated no differences in PR interval between any groups, but we observed a widened QRS interval in MI animals as compared with sham-operated control animals over the 9 weeks study. This intraventricular conduction delay was not influenced by T 3 supplementation. Echocardiography at all time points (1, 3, 5, 7, and 9 weeks), demonstrated that the anterior wall was significantly thinner in diastole and systole in MI-saline hearts versus Sham controls ( Figure 4B and 4C) . Overall, posterior wall thickness was similar in MI-saline and Sham controls throughout the study ( Figure 4D and 4E ). Administration of T 3 at any dose, overall, did not alter anterior or posterior wall thickness during systole or diastole, suggesting that T 3 replacement in rats with CHF does not alter LV structure or mass.
T 3 Infusion Does Not Prevent LV Remodeling
LV chamber volumes during diastole and systole were significantly greater in MI-saline versus Sham controls, ( Figure 5A and 5B) . Accordingly, LV fractional shortening and ejection fraction were significantly attenuated in MIsaline versus Sham controls ( Figure 5C and 5D ). Importantly, LV volume in systole and diastole increased over time in MI-saline animals ( Figure 5A and 5B) . In regard to T 3 infusion, there was no effect of any dose on LV chamber volumes during systole or diastole, or on fractional shortening or ejection fraction.
T 3 Administration Increases LV Contractility in CHF Rats
At 9 weeks, rats were anesthetized and LV contractility and relaxation were measured with a high-fidelity pressure-volume catheter. As seen in Figure 6A , LV contractility (ϩdP/dt max) and relaxation rate (half-time to relaxation [], Figure 6B ) were significantly (PϽ0.001) attenuated in MI animals versus Sham controls (4773Ϯ259 versus 6310Ϯ267 mm Hg/s, and 15.87Ϯ1.23 versus 11.11Ϯ0.25 ms, respectively). Contractility was significantly improved by administration of both 6 g and 60 gT 3 /kg/d (PϽ0.05). A similar trend was observed for measurements of , but the improvement in diastolic function did not achieve statistical significance (Pϭ0.10). In addition, there were no further significant differences in cardiac function under conditions of reduced preload (suprarenal venous occlusion) or ␤ 1 -adrenergic stimulation (dobutamine 20 g/kg) between MI-saline and T 3 -treated groups (data not shown).
Myocardial Gene Expression
To determine whether the physiological changes that occur after MI and in response to thyroid hormone are mediated, at least in part, by transcriptional changes, we measured the expression of both myosin heavy chain genes. Expression of the cardiac specific ␣-MHC gene was significantly (PϽ0.001) attenuated in MI-saline animals (to 23Ϯ5% of controls) and dose dependently increased with T 3 replacement at 6 and 60 g/kg/d to 42Ϯ4% and 150Ϯ14% of controls (PϽ0.05), respectively ( Figure 7A ). Beta-MHC expression was significantly reduced by T 3 replacement at 6 and 60 g/kg/d to 71Ϯ12% and 73Ϯ21% of controls (PϽ0.05), respectively ( Figure 7B ).
Discussion
The present studies were designed to test the hypothesis that physiological replacement of T 3 to MI-induced CHF animals would improve or restore LV contractile performance. The major finding of the present study is T 3 replacement initiated 1 week after a MI, after the majority of LV remodeling has taken place, can improve LV contractility. It is well known that hypothyroid patients have low cardiac output, increased systemic vascular resistance and impaired LV contractility and relaxation. 30, 31 These effects are due to thyroid hormone mediated changes in systemic vascular resistance as well as direct effects on myocyte gene expression. 1, 32 Therefore, the chronic decreases in T 3 concentrations in heart failure patients may further contribute to the development of pathological hypertrophy post-MI. 33, 34 
T 3 Replacement
Proof of concept studies by Hamilton et al 16 and recent studies by Pingitore et al 18 have shown that physiological T 3 replacement can produce hemodynamic benefits. Hamilton et al had previously shown that short-term administration of T 3 could be safely infused into patients with advanced heart disease to reduce afterload and increase cardiac output. Multiple studies of T 3 infusion to both adults and children undergoing cardiac surgery have shown that correcting low T 3 levels improves cardiovascular function. [35] [36] [37] [38] Additionally, administration of T 3 has also been shown to decrease plasma noradrenaline, aldosterone, and natriuretic peptide concentrations, which are frequently elevated in heart failure patients. 18 Most importantly, all human studies to date have confirmed the safety and lack of untoward side effects associated with the replacement of T 3 to euthyroid levels. [35] [36] [37] [38] [39] 
MI Animal Model
In the current study, the level of LV dysfunction induced by coronary artery ligation was assessed 1 week post-MI surgery to appropriately divide animals into experimental groups. In MI-saline animals, LV function measured by serial echocardiography and LV catheterization at 9 weeks was significantly attenuated throughout the study versus Sham-operated controls. Serum T 4 and T 3 levels were significantly lower 1 week post-MI (PϽ0.05) and remained significantly lower for at least 5 weeks. These data are similar to the previous observation by Olivares et al who conducted a time course study of thyroid function after a MI in a rodent model. 40 This group noted that post-MI serum T 3 levels were significantly depressed and the ejection fraction was reduced by 50%.
The mechanism for the low T 3 syndrome in heart failure patients is currently under investigation. Low T 3 levels are associated with increased production of proinflammatory cytokines and/or increased clearance of T 3 . Interleukins 1 and 6 were shown to competitively inhibit coactivators for type 1 deiodinase transcription, 41 an enzyme which converts T 4 to T 3 but also converts T 4 and T 3 to inactive isomers. Increased clearance of T 3 may also be attributed to increased type III deiodinase (D3) expression or activity which is increased in heart failure animal models. 40, 42, 43 D3 reduces T 3 concentrations by preventing its production (converting T 4 to inactive T 3 ), and increasing its degradation (converting T 3 to diiodothyronine). Simonides et al, 42 recently demonstrated that D3 expression can be activated by hypoxia inducible factor-1. During the early compensatory stages of a MI, hypoxia inducible factor-1 expression is increased in human hearts, 44 and is also expressed in the nonischemic mechanically stressed myocardium in MI-rodent models. 45 If hypoxia inducible factor-1 levels subside over time, D3 expression would be attenuated. Such an effect would prevent T 4 and T 3 degradation and may explain the gradual increase in serum T 4 and T 3 concentrations in MI-saline animals in this study.
T 3 Replacement and LV Function
For these studies, T 3 replacement was initiated 1 week post-MI, after significant LV remodeling had taken place. Recently, Chen et al, demonstrated that intraperitoneal injection of T 3 at 14 g/kg/d shortly after MI surgery and continued for 3 days, reduced cardiac myocyte apoptosis along the border zone of the infarct in rats. 46 Similarly, Pantos et al 47 demonstrated that immediate T 4 supplementation, after a MI in a rodent model, improves cardiac function and prevents cardiac remodeling. In both studies, heart rates and T 3 concentrations were significantly elevated suggesting that animals were thyrotoxic. It remains to be determined whether immediate T 3 "replacement" can attenu- ate the early stages of LV remodeling and improve LV function. In T 3 replacement animals, LV end diastolic volume continued to increase over the 9 weeks study. Although T 3 replacement did not prevent long-term LV remodeling, it improved LV contractility and relaxation in the remaining viable myocardium. These data suggest that the activation of T 3 dependent signaling pathways at the onset of an MI may promote angiogenesis and cell survival and reduce the morbidity and mortality associated with CHF.
Gene Expression
In the euthyroid rat ventricle, ␣-MHC is the predominant MHC isoform. The ␣-MHC gene is positively regulated by T 3 , whereas the ␤-MHC gene is negatively regulated. In the hypothyroid rat heart, as well as after MI and in heart failure, ␤-MHC expression predominates and ␣-MHC expression is reduced. The effect of heart failure on ␣and ␤-MHC expression and the reversal with T 3 supplementation have been previously reported. 20, 48 Similar to a prior study from our laboratory, we measured a significant reduction in ␣-MHC expression in our post-MI animals. 20 In the current study, we found that 6 gT 3 /kg/d significantly decreased ␤-MHC expression as well as increased ␣-MHC expression. These data reflect the relative sensitivity of the cardiac MHC genes to changes in serum T 3 concentrations.
Conclusion
Overall, these studies suggest that long-term T 3 replacement to euthyroid levels initiated 1 week post-MI significantly improves LV function primarily through an increase in contractility. This effect may be linked to changes in ␣and ␤-MHC expression. LV chamber size and remodeling were not reversed by T 3 replacement when initiated after significant LV remodeling has taken place. It remains to be determined whether LV remodeling can be reversed in heart failure patients by the immediate administration of T 3 and whether this can be accomplished by returning myocardial T 3 concentrations to euthyroid levels. 
